Lodewyk Wessels

Professor

Delft University of Technology
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (39)

Studies have identified a link between specific microbiome-derived bacteria and immune checkpoint blockade (ICB) efficacy. However, these species lack consistency across studies, and their immunomodulatory mechanisms remain elusive. To understand the influence of the microbiome on ICB response, we studied its functional capacity. Using pan-cancer metagenomics data from ICB-treated patients, we showed that community-level metabolic pathways are stable across individuals, making them suitable for predicting ICB response. We identified several microbial metabolic processes significantly associated with response, including the methylerythritol 4-phosphate (MEP) pathway, which was associated with response and induced Vδ2 T cell–mediated antitumor responses in patient-derived tumor organoids. In contrast, riboflavin synthesis was associated with ICB resistance, and its intermediates induced mucosal-associated invariant T (MAIT) cell–mediated immune suppression. Moreover, gut metabolomics revealed that high riboflavin levels were linked to worse survival in patients with abundant intratumoral MAIT cells. Collectively, our results highlight the relevance of metabolite-mediated microbiome–immune cell cross-talk. Significance: Microbial metabolic pathways are highly conserved across individuals and therefore offer an opportunity to link the microbiome to immunotherapy efficacy. We identified specific microbial metabolic pathways associated with response to ICB and provided mechanistic insights into the immunomodulatory influence of these pathways on antitumor immunity.

Year:

2026

Zinc finger proteins (ZNFs) are the largest family of transcription factors, yet how they activate gene expression remains unclear. In this study, we identified Zincore, a protein complex consisting of QRICH1 and SEPHS1, as a ZNF-specific coregulator essential for embryonic development in mice and associated with developmental syndromes in humans. We also identified ZFP91 as a representative Zincore client, binding the conserved promoter motif CTTTAAR. Cryo–electron microscopy of a Zincore-ZFP91-DNA complex revealed a SEPHS1 arginine clamp to recognize the DNA-bound zinc finger domains. This mode of binding explains recognition of different ZNFs and stabilizes ZFP91 onto its cognate DNA motif. Thus, our study identified Zincore as a ZNF-specific coregulator essential for development, involving a distinctive mechanism that locks ZNFs onto DNA and regulates transcription.

Year:

2025

Perturbation response models (PRMs) predict transcriptional responses to interventions such as gene knockout or drug treatments. While simple baseline models match PRMs in reconstructing post-treatment profiles, we show that drug response predictors trained on PRM-generated profiles significantly outperform those trained on baseline or pre-treatment profiles. Unlike simple baseline models, PRMs preserve variation in response-relevant genes, making them a highly valuable tool for predicting drug response.

Year:

2025

Silencing of apoptotic pathway genes confers resistance to agonists of the death receptor pathway. Volcano plots of genes enriched or depleted for gRNA when rTRAIL-treated cells were compared with DMSO vehicle control cells following transduction with a genome-wide CRISPR/Cas9 library in MSTO-211H mesothelioma ( A ) and PC-9 lung adenocarcinoma ( B ) cells. Each dot represents gene-wise scores for MAGeCK gene level analysis with genes of interest highlighted. The dotted line indicates an FDR of 0.1. x -axis, log 2 fold change of mean gRNA reads per genes comparing treatment to DMSO replicates. y -axis, −log 10 FDR for genes based upon their negative (pink and red dots) and positive (blue dots) fold change and FDR calculated by the MAGeCK algorithm. C, Confirmation of deletion of target apoptotic genes following transfection with synthetic crRNA in MSTO-211H, NCI-H28, and H2804 cancer cells. D, Six-day viability assay in MSTO-211H cells following deletion of specific apoptotic genes and treatment with either rTRAIL or MEDI3039. y -axis: viability effect relative to control cells. E, Volcano plots as in A and B illustrating results of SAM CRISPR activatory screen in PC-9 cells treated with rTRAIL. F, MSTO-211H isogenic cell lines were screened versus the parental cell line with a concentration range of 60 compounds and viability measured at day 6. The AUC values for each isogenic cell line and the matched parental Cas9 line were subtracted to calculate a ΔAUC value, with high (positive) values indicating increased resistance to that compound in the isogenic lines, and low (negative) values increased sensitivity. x -axis: name of compounds screened. y -axis: ΔAUC values.

Year:

2025

In vivo expression of CASP8 and CFLAR (FLIP) modulate response to MEDI3039 in PDX models. A, Change in percent tumor growth from baseline was measured at day 18 in 18 CRC PDX models treated with a fixed dose of MEDI3039. B, Tumor plots of responder, nonresponder, and partial response models. x -axis, days; y -axis, tumor volume. Arrows indicate treatment with MEDI3039. Red line, MEDI039-treated mice; blue line, untreated mice. C, Tumor CASP8 mRNA expression in PDX nonresponders (red) and responders (blue) with MEDI3039 (each circle represents a tumor from a single mouse). D, Comparison of CASP8:CFLAR ratio in MEDI3039 responder (blue) and nonresponder (red) PDX models.

Year:

2025

MEDI3039 sensitivity is significantly affected by FLIP(L)–caspase-8 ratio. A, Percentage cell death at 24 hours post MEDI3039 10 pmol/L in a panel of colorectal cell lines. B, Scatter plot of summary correlation analysis of cell death protein expression and percent cell death induced in response to MEDI3039 across panel of colorectal cancer cell lines. C, CASP8/FLIP or CASP8/MCL1 ratio protein expression versus MEDI3039-induced cell death. Each circle indicates a cell line. MEDI3039 AUC for cell lines for different cell types split according to discretized CASP8/FLIP ( D ) or CASP8/MCL1 ( E ) ratio (mRNA expression).

Year:

2025

Sensitivity of cancer cell lines to MEDI3039. A panel of 758 cancer cell lines was treated for 6 days with a concentration range of the death receptor agonist MEDI3039 and viability measured as AUC. A, Frequency distribution plot illustrating bimodal distribution of MEDI3039 AUC values for solid (green) and hematopoietic (blue) cell lines. B, AUC values with SD error bars for each cell line (circles) in 19 tissue types and individually colored according to high or low CASP8 mRNA expression as defined by the bimodal mid-point. C, Plot of cell line expression of most significant CASP8 microarray probeset ranked on the basis of sensitivity to MEDI3039. D, A two-tailed t test was calculated for 30 tissue types using MEDI3039 AUC values and CASP8 expression, and the P value indicated ( E ) predictive 9 probeset (7 gene) predictive geneset identified by vSURF random forest analysis of microarray data. F, AUC plot demonstrating ability of 9 probeset predictive geneset to classify solid cell lines as “sensitive” or “resistant.” See Supplementary Fig. S2B for description of cancer type abbreviations used in B and D .

Year:

2025

Drug combinations to overcome rTRAIL resistance in isogenic cell lines. A, Isogenic MSTO-211H cell lines were screened against 59 compounds in combination with a fixed dose of MEDI3039 (100 pmol/L). Viability was measured at day 6. For each combination, a ΔAUC was calculated by subtracting the observed from the expected AUC (based upon the activity of the MEDI3039 concentration as a single agent). Values >0.2 are indicative of synergy. x -axis: name of compounds screened. Bid-KO MSTO-211H or Bid-mutant Sup-T1 cells were treated with a concentration range of the IAP inhibitor AZD5582 ( B ) or LCL161 ( C ) for 6 days (blue line) or in combination with a fixed concentration of MEDI3039 (green, IC 90 values of parental cell line). Indicated is the effect of the fixed concentration of MEDI3039 (red dotted) and the expected (additive) effect of the combination (gray dotted). x -axis: log 10 scale concentration range. y -axis: relative viability effect. D, Clonogenic survival assays at day 14 in Cas9 versus crBID MSTO-211H and PC-9 cells treated with the indicated IAP inhibitors AZD and LCL161 as single agents or combined with MEDI3039. AZD, AZD5582. E, Annexin V/PI staining of Cas9 versus BID KO MSTO-211H and PC-9 cells following 24-hour treatment with MEDI3039 ±10 nmol/L AZD5582.

Year:

2025

Immune checkpoint blockade has led to paradigm shifts in the treatment of various tumour types 1–4 , yet limited efficacy has been observed in patients with metastatic mismatch-repair-proficient (pMMR) colorectal cancer 5 . Here we report clinical results and in-depth analysis of patients with early-stage pMMR colon cancer from the phase II NICHE study (ClinicalTrials.gov: NCT03026140). A total of 31 patients received neoadjuvant treatment of nivolumab plus ipilimumab followed by surgery. The response rate was 26% and included six patients with a major pathological response (10% or less residual viable tumour). One patient with an ongoing clinical complete response did not undergo surgery. Circulating tumour DNA was positive in 26 of 31 patients at baseline, and clearance was observed in 5 of 6 responders before surgery, whereas 19 of 20 non-responders remained circulating tumour DNA positive. Responses were observed despite a low tumour mutational burden in all tumours, whereas chromosomal genomic instability scores were significantly higher in responders than in non-responders. Furthermore, responding tumours had significantly higher baseline expression of proliferation signatures and TCF1, and imaging mass cytometry revealed a higher percentage of Ki-67 + cancer and Ki-67 + CD8 + T cells in responders than in non-responders. These results provide a comprehensive analysis of response to neoadjuvant immune checkpoint blockade in early-stage pMMR colon cancers and identify potential biomarkers for patient selection.

Year:

2025

Studies have identified a link between specific microbiome-derived bacteria and immune checkpoint blockade (ICB) efficacy. However, these species lack consistency across studies, and their immunomodulatory mechanisms remain elusive. To understand the influence of the microbiome on ICB response, we studied its functional capacity. Using pan-cancer metagenomics data from ICB-treated patients, we showed that community-level metabolic pathways are stable across individuals, making them suitable for predicting ICB response. We identified several microbial metabolic processes significantly associated with response, including the methylerythritol 4-phosphate (MEP) pathway, which was associated with response and induced Vδ2 T cell–mediated antitumor responses in patient-derived tumor organoids. In contrast, riboflavin synthesis was associated with ICB resistance, and its intermediates induced mucosal-associated invariant T (MAIT) cell–mediated immune suppression. Moreover, gut metabolomics revealed that high riboflavin levels were linked to worse survival in patients with abundant intratumoral MAIT cells. Collectively, our results highlight the relevance of metabolite-mediated microbiome–immune cell cross-talk. Significance: Microbial metabolic pathways are highly conserved across individuals and therefore offer an opportunity to link the microbiome to immunotherapy efficacy. We identified specific microbial metabolic pathways associated with response to ICB and provided mechanistic insights into the immunomodulatory influence of these pathways on antitumor immunity.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (42)

John Ladbury

Professor and Director of Leeds Centre for Disease Models

University of Leeds

UNITED KINGDOM
View details

Britt Suelmann

University Medical Center Utrecht, Utrecht University

NETHERLANDS
View details

Katarzyna Joanna Jerzak

University of Toronto

CANADA
View details

Marcel Reinders

Delft University of Technology

NETHERLANDS
View details

Maarten Altelaar

Professor

Utrecht University

NETHERLANDS
View details

Boudewijn Burgering

University Medical Center Groningen

NETHERLANDS
View details

Joachim G. Aerts

head of department

Erasmus MC

NETHERLANDS
View details

Patrick Neven

University Hospitals Leuven

BELGIUM
View details

Kristel Van Calsteren

KU Leuven

BELGIUM
View details

Niven Mehra

Group Leader

Radboud University Medical Center

NETHERLANDS
View details

Klaas Mulder

Tenured Group Leader - Associate Professor

Radboud University

NETHERLANDS
View details

Diether Lambrechts

Science Director

KU Leuven

BELGIUM
View details

Richard Meijer

Professor; Head Dept Oncological Urology

University Medical Center Groningen

NETHERLANDS
View details

Carla M.L. van Herpen

Radboud University Medical Center

NETHERLANDS
View details

Adriaan D. Bins

-

NETHERLANDS
View details

Daniel Longley

The Queen's University Belfast

UNITED KINGDOM
View details

Krijn Dijkstra

The Netherlands Cancer Institute

NETHERLANDS
View details

Patrick Celie

head of facility

Antoni van Leeuwenhoek Nederlands Kanker Instituut

NETHERLANDS
View details

Ann Hoeben

Maastricht University Medical Centre

NETHERLANDS
View details

Kim Monkhorst

The Netherlands Cancer Institute

NETHERLANDS
View details

Ton Schumacher

Principal Investigator

Oncode Institute

NETHERLANDS
View details

Evert Bosdriesz

Assistant professor

University of Amsterdam

NETHERLANDS
View details

Marieke van de Ven

Head of Mouse Cancer Clinic

-

NETHERLANDS
View details

Marleen Kok

Principal Investigator

The Netherlands Cancer Institute

NETHERLANDS
View details

Henk Verheul

Professor of Medical Oncology

Erasmus MC

NETHERLANDS
View details

Noel de Miranda

Professor

Leiden University Medical Center

NETHERLANDS
View details

Frédéric Amant

Antoni van Leeuwenhoek Nederlands Kanker Instituut

NETHERLANDS
View details

Mariette Labots

VU medisch centrum

NETHERLANDS
View details

John Haanen

Chair of Translational Immunotherapy of Cancer

Leiden University Medical Center

NETHERLANDS
View details

Catrin Lutz

The Netherlands Cancer Institute

NETHERLANDS
View details

Anastassis Perrakis

Principal Investigator

Antoni van Leeuwenhoek Nederlands Kanker Instituut

NETHERLANDS
View details

Ellen Warner

University of Toronto

CANADA
View details

Marcel de Zoete

University Medical Center Groningen

NETHERLANDS
View details

Magali Michaut

Københavns Universitet

DENMARK
View details

Hans Gelderblom

Prof.dr

Leiden University Medical Center

NETHERLANDS
View details

Corinna Ernst

Hannover Medical School

GERMANY
View details

Charlotte Maggen

Vrije Universiteit Brussel

BELGIUM
View details

Egbert Smit

Leiden University Medical Center

NETHERLANDS
View details

Jochen Prehn

Royal College of Surgeons in Ireland

IRELAND
View details

Simon McDade

The Queen's University Belfast

UNITED KINGDOM
View details

Fedro Peccatori

Director, Fertility nd Procreation in Oncology Unit

European Institute of Oncology

ITALY
View details

Michiel Vermeulen

Senior group leader

Radboud Universiteit Nijmegen

NETHERLANDS
View details